Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Free Cash Flow (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Free Cash Flow data on record, last reported at -$9.4 million in Q3 2025.

  • For Q3 2025, Free Cash Flow fell 20.09% year-over-year to -$9.4 million; the TTM value through Sep 2025 reached -$50.3 million, down 6.97%, while the annual FY2024 figure was -$41.4 million, 35.75% up from the prior year.
  • Free Cash Flow reached -$9.4 million in Q3 2025 per SNTI's latest filing, up from -$13.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$934675.0 in Q2 2021 and bottomed at -$24.3 million in Q3 2022.
  • Average Free Cash Flow over 5 years is -$12.6 million, with a median of -$13.4 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: crashed 1714.0% in 2022, then skyrocketed 78.61% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$5.1 million in 2021, then plummeted by 242.07% to -$17.5 million in 2022, then fell by 8.74% to -$19.1 million in 2023, then increased by 29.27% to -$13.5 million in 2024, then grew by 29.97% to -$9.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$9.4 million in Q3 2025, -$13.3 million in Q2 2025, and -$14.0 million in Q1 2025.